RG
IBRX icon

Rathbones Group’s ImmunityBio IBRX Stock Holding History

Rathbones Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
163,220
+9,800
+6% +$74.2K 0.01% 334
2026
Q1 		$1.18M Sell
153,420
-8,000
-5% -$54.8K ﹤0.01% 342
2025
Q4 		$320K Hold
161,420
– – ﹤0.01% 511
2025
Q3 		$397K Buy
161,420
+44,000
+37% +$113K ﹤0.01% 473
2025
Q2 		$310K Buy
117,420
+20,800
+22% +$55.9K ﹤0.01% 496
2025
Q1 		$291K Buy
96,620
+7,200
+8% +$21.8K ﹤0.01% 466
2024
Q4 		$229K Buy
89,420
+16,000
+22% +$66.7K ﹤0.01% 509
2024
Q3 		$273K Hold
73,420
– – ﹤0.01% 500
2024
Q2 		$464K Hold
73,420
– – ﹤0.01% 423
2024
Q1 		$394K Hold
73,420
– – ﹤0.01% 448
2023
Q4 		$369K Hold
73,420
– – ﹤0.01% 446
2023
Q3 		$124K Buy
+73,420
New +$147K ﹤0.01% 566

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rathbones Group's IBRX Position: Q2 2026 in Review

Rathbones Group increased its ImmunityBio (IBRX) stake by 6.4% in Q2 2026, buying an estimated $74.2K and bringing the position to 163,220 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #334.

Rathbones Group first reported a position in IBRX in Q3 2023 and has held it in 12 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Rathbones Group held 163,220 shares of ImmunityBio worth $1.43M as of Q2 2026.
  • Rathbones Group bought 9,800 ImmunityBio shares in Q2 2026, an estimated $74.2K.
  • ImmunityBio made up 0.01% of Rathbones Group's portfolio in Q2 2026, its #334 holding.
  • Rathbones Group first reported a position in ImmunityBio in Q3 2023 and has held it in 12 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.